CytoDyn (CYDY) Change in Accured Expenses (2010 - 2026)

CytoDyn's Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$4.0 million for Q1 2026.

• Quarterly Change in Accured Expenses fell 532.44% year-over-year to -$4.0 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $15.5 million (up 295.74% YoY) and the FY2025 annual result came in at -$11.3 million, down 205.27% from the prior year.
• Change in Accured Expenses was -$4.0 million for Q1 2026 at CytoDyn, down from $17.6 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $17.6 million in Q4 2025 and bottomed at -$14.3 million in Q3 2024.
• A 5-year average of $1.5 million and a median of $988000.0 in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 2028.57% — and 2026, when it tumbled 532.44%.
• CytoDyn's Change in Accured Expenses stood at -$205000.0 in 2022, then jumped by 615.12% to $1.1 million in 2023, then decreased by 0.19% to $1.1 million in 2024, then surged by 1567.55% to $17.6 million in 2025, then slumped by 122.83% to -$4.0 million in 2026.
• Business Quant data shows CYDY's Change in Accured Expenses at -$4.0 million in Q1 2026, $17.6 million in Q4 2025, and $918000.0 in Q3 2025.